Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases

Biomedicine and Pharmacotherapy

Volumn 110, Issue , 2019, Pages 775-785

  Fallah, Asghar ^a,b   Sadeghinia, Ali ^a   Kahroba, Houman ^a   Samadi, Amin ^c   Heidari, Hamid Reza ^a   Bradaran, Behzad ^a   Zeinali, Sirous ^d   Molavi, Ommoleila ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF ALBERTA   (Canada)

^d PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Angiogenesis dependent diseases; Anti angiogenesis; Anti angiogenic therapeutics; Cancer; VEGF VEGFR system receptors

Indexed keywords

ANGIOSTATIN; ENDOSTATIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; CYTOKINE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; DIABETIC RETINOPATHY; GENE THERAPY; HUMAN; MALIGNANT NEOPLASM; MOLECULARLY TARGETED THERAPY; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; CYTOKINES; DRUG DELIVERY SYSTEMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85058244020     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2018.12.022     Document Type: Review

References (137)

1. Folkman, J., Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 6:4 (2007), 273–286.
2. Ribatti, D., The history of angiogenesis inhibitors. Leukemia, 21(8), 2007, 1606.
3. Potente, M., Mäkinen, T., Vascular heterogeneity and specialization in development and disease. Nat. Rev. Mol. Cell Biol., 2017.
4. Ferrara, N., Kerbel, R.S., Angiogenesis as a therapeutic target. Nature 438:7070 (2005), 967–974.
5. Rouwkema, J., Khademhosseini, A., Vascularization and angiogenesis in tissue engineering: beyond creating static networks. Trends Biotechnol. 34:9 (2016), 733–745.
6. Luttun, A., Tjwa, M., Carmeliet, P., Placental growth factor (PlGF) and its receptor Flt‐1 (VEGFR‐1). Ann. N. Y. Acad. Sci. 979:1 (2002), 80–93.
7. De Vries, C., Escobedo, J.A., Ueno, H., Houck, K., Ferrara, N., Williams, L.T., The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 1992, 989–991.
8. Shahneh, F.Z., Baradaran, B., Zamani, F., Aghebati-Maleki, L., Tumor angiogenesis and anti-angiogenic therapies. Hum. Antibodies 22:1–2 (2013), 15–19.
9. Ribatti, D., The discovery of angiogenic growth factors: the contribution of Italian scientists.., 6(1), 2014, 8.
10. Ucuzian, A.A., Gassman, A.A., East, A.T., Greisler, H.P., Molecular mediators of angiogenesis. J. Burn Care Res. 31:1 (2010), 158–175.
11. Fagiani, E., Christofori, G., Angiopoietins in angiogenesis. Cancer Lett. 328:1 (2013), 18–26.
12. Augustin, H.G., Koh, G.Y., Thurston, G., Alitalo, K., Control of vascular morphogenesis and homeostasis through the angiopoietin–tie system. Nat. Rev. Mol. Cell Biol., 10(3), 2009, 165.
13. De Palma, M., Biziato, D., Petrova, T.V., Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer, 17(8), 2017, 457.
14. Zhao, J., Chen, L., Shu, B., Tang, J., Zhang, L., Xie, J., Qi, S., Xu, Y., Granulocyte/macrophage colony-stimulating factor influences angiogenesis by regulating the coordinated expression of VEGF and the Ang/Tie system. PLoS One, 9(3), 2014, e92691.
15. Siavashi, V., Sariri, R., Nassiri, S.M., Esmaeilivand, M., Asadian, S., Cheraghi, H., Barekati-Mowahed, M., Rahbarghazi, R., Angiogenic activity of endothelial progenitor cells through angiopoietin-1 and angiopoietin-2. Anim. Cells Syst. 20:3 (2016), 118–129.
16. Teven, C.M., Farina, E.M., Rivas, J., Reid, R.R., Fibroblast growth factor (FGF) signaling in development and skeletal diseases. Genes Dis. 1:2 (2014), 199–213.
17. Yun, Y.-R., Won, J.E., Jeon, E., Lee, S., Kang, W., Jo, H., Jang, J.-H., Shin, U.S., Kim, H.-W., Fibroblast growth factors: biology, function, and application for tissue regeneration. J. Tissue Eng., 1(1), 2010, 218142.
18. Kimáková P., Solár, P., Solárová Z., Komel, R., Debeljak, N., Erythropoietin and its angiogenic activity. Int. J. Mol. Sci., 18(7), 2017, 1519.
19. Ferrara, N., VEGF and intraocular neovascularization: from discovery to therapy. Transl. Vis. Sci. Technol., 5(2), 2016, 10.
20. Ferrara, N., Damico, L., Shams, N., Lowman, H., Kim, R., Development of ranibizumab, an anti–vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:8 (2006), 859–870.
21. Hillen, F., Griffioen, A.W., Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev. 26:3-4 (2007), 489–502.
22. Ribatti, D., Crivellato, E., “Sprouting angiogenesis” a reappraisal. Dev. Biol. 372:2 (2012), 157–165.
23. Norton, K.-A., Popel, A.S., Effects of endothelial cell proliferation and migration rates in a computational model of sprouting angiogenesis. Sci. Rep., 6, 2016.
24. Mentzer, S.J., Konerding, M.A., Intussusceptive angiogenesis: expansion and remodeling of microvascular networks. Angiogenesis 17:3 (2014), 499–509.
25. Kimura, K., Hashiguchi, T., Deguchi, T., Horinouchi, S., Uto, T., Oku, H., Setoyama, S., Maruyama, I., Osame, M., Arimura, K., Serum VEGF—as a prognostic factor of atherosclerosis. Atherosclerosis 194:1 (2007), 182–188.
26. Kerbel, R.S., Tumor angiogenesis. N. Engl. J. Med. 358:19 (2008), 2039–2049.
27. Weis, S.M., Cheresh, D.A., Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 17:11 (2011), 1359–1370.
28. Bandello, F., Sacconi, R., Querques, L., Corbelli, E., Cicinelli, M.V., Querques, G., Recent advances in the management of dry age-related macular degeneration: a review. F1000Research, 6, 2017.
29. Ambati, J., Fowler, B.J., Mechanisms of age-related macular degeneration. Neuron 75:1 (2012), 26–39.
30. Consortium, A.G., Seven new loci associated with age-related macular degeneration. Nat. Genet. 45:4 (2013), 433–439.
31. Doyle, S.L., Campbell, M., Ozaki, E., Salomon, R.G., Mori, A., Kenna, P.F., Farrar, G.J., Kiang, A.-S., Humphries, M.M., Lavelle, E.C., NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat. Med. 18:5 (2012), 791–798.
32. Duh, E.J., Sun, J.K., Stitt, A.W., Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight, 2(14), 2017.
33. Bolinger, M.T., Antonetti, D.A., Moving past anti-VEGF: novel therapies for treating diabetic retinopathy. Int. J. Mol. Sci., 17(9), 2016, 1498.
34. Gale, R., Scanlon, P.H., Evans, M., Ghanchi, F., Yang, Y., Silvestri, G., Freeman, M., Maisey, A., Napier, J., Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease. Eye 31 (2017), S1–S20.
35. Safi, S.Z., Qvist, R., Kumar, S., Batumalaie, K., Ismail, I.S.B., Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets. Biomed Res. Int., 2014, 2014.
36. Curtis, T., Gardiner, T., Stitt, A., Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis?. Eye 23:7 (2009), 1496–1508.
37. Committee, S., Cancer progress report. Clin. Cancer Res., 21(19 Suppl), 2015, S1.
38. Benny, O., Fainaru, O., Adini, A., Cassiola, F., Bazinet, L., Adini, I., Pravda, E., Nahmias, Y., Koirala, S., Corfas, G., An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat. Biotechnol. 26:7 (2008), 799–807.
39. Folkman, J., Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:21 (1971), 1182–1186.
40. Ferrara, N., Hillan, K.J., Gerber, H.-P., Novotny, W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3:5 (2004), 391–400.
41. Masoud, G.N., Li, W., HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm. Sin. B 5:5 (2015), 378–389.
42. O'Reilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W.S., Flynn, E., Birkhead, J.R., Olsen, B.R., Folkman, J., Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:2 (1997), 277–285.
43. Shen, Z., Yao, C., Wang, Z., Yue, L., Fang, Z., Yao, H., Lin, F., Zhao, H., Sun, Y.-J., Bian, X.-w., Vastatin, an endogenous antiangiogenesis polypeptide that is lost in hepatocellular carcinoma, effectively inhibits tumor metastasis. Mol. Ther. 24:8 (2016), 1358–1368.
44. Goel, S., Duda, D.G., Xu, L., Munn, L.L., Boucher, Y., Fukumura, D., Jain, R.K., Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 91:3 (2011), 1071–1121.
45. Eales, K., Hollinshead, K., Tennant, D., Hypoxia and metabolic adaptation of cancer cells. Oncogenesis, 5(1), 2016, e190.
46. Nerini, I.F., Cesca, M., Bizzaro, F., Giavazzi, R., Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. Chin. J. Cancer, 35(1), 2016, 61.
47. Goel, S., Wong, A.H.-K., Jain, R.K., Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb. Perspect. Med., 2(3), 2012, a006486.
48. Hosaka, K., Yang, Y., Seki, T., Fischer, C., Dubey, O., Fredlund, E., Hartman, J., Religa, P., Morikawa, H., Ishii, Y., Pericyte–fibroblast transition promotes tumor growth and metastasis. Proc. Natl. Acad. Sci. 113:38 (2016), E5618–E5627.
49. Lu, J., Shenoy, A.K., Epithelial-to-pericyte transition in cancer. Cancers, 9(7), 2017, 77.
50. Ferland-McCollough, D., Slater, S., Richard, J., Reni, C., Mangialardi, G., Pericytes, an overlooked player in vascular pathobiology. Pharmacol. Ther. 171 (2017), 30–42.
51. Chen, Z., Xu, X., Hu, J., Role of pericytes in angiogenesis: focus on cancer angiogenesis and anti-angiogenic therapy. Neoplasma 63:2 (2016), 173–182.
52. Abdalla, A.M., Xiao, L., Ullah, M.W., Yu, M., Ouyang, C., Yang, G., Current challenges of cancer anti-angiogenic therapy and the promise of nanotherapeutics. Theranostics, 8(2), 2018, 533.
53. Leader, B., Baca, Q.J., Golan, D.E., Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7:1 (2008), 21–39.
54. Ohlfest, J.R., Demorest, Z.L., Motooka, Y., Vengco, I., Oh, S., Chen, E., Scappaticci, F.A., Saplis, R.J., Ekker, S.C., Low, W.C., Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol. Ther. 12:5 (2005), 778–788.
55. de BONO, J.S., Ashworth, A., Translating cancer research into targeted therapeutics. Nature, 467(7315), 2010, 543.
56. De Palma, M., Hanahan, D., The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol. Oncol. 6:2 (2012), 111–127.
57. Mangoni, A.A., Woodman, R.J., Kichenadasse, G., Rowland, A., Sorich, M.J., Anti-VEGF-Induced Hypertension and Cancer Outcomes: Translating Research Into Clinical Practice. 2016, Taylor & Francis.
58. Tabchi, S., Blais, N., Antiangiogenesis for advanced non-small-cell lung cancer in the era of immunotherapy and personalized medicine. Front. Oncol., 7, 2017.
59. Pavelić K., Martinović T., Pavelić S.K., Do we understand the personalized medicine paradigm?. EMBO Rep. 16:2 (2015), 133–136.
60. Pritchard, D.E., Moeckel, F., Villa, M.S., Housman, L.T., McCarty, C.A., McLeod, H.L., Strategies for integrating personalized medicine into healthcare practice. Per. Med. 14:2 (2017), 141–152.
61. Carmeliet, P., Angiogenesis in life, disease and medicine. Nature 438:7070 (2005), 932–936.
62. Luo, W., Shih, Y., Lo, W., Chen, H., Wang, S., Wang, C., Chien, C., Chiang, C., Chuang, Y., Hu, Y., Baculovirus vectors for antiangiogenesis-based cancer gene therapy. Cancer Gene Ther. 18:9 (2011), 637–645.
63. Fleetwood, F., Klint, S., Hanze, M., Gunneriusson, E., Frejd, F.Y., Ståhl, S., Löfblom, J., Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity. Sci. Rep., 4, 2014.
64. Zhang, Q., Chen, G., Liu, X., Qian, Q., Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Res. 17:2 (2007), 89–99.
65. Niu, G., Chen, X., Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr. Drug Targets 11:8 (2010), 1000–1017.
66. Zinser-Sierra, J.W., Rodríguez-Ramírez, S., Villalobos-Valencia, R., Ramírez-Márquez, M., Use of Bevacizumab in metastatic colorectal cancer. Drugs R & D 11:2 (2011), 101–111.
67. Weiner, L.M., Surana, R., Wang, S., Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10:5 (2010), 317–327.
68. Pozzi, C., Cuomo, A., Spadoni, I., Magni, E., Silvola, A., Conte, A., Sigismund, S., Ravenda, P.S., Bonaldi, T., Zampino, M.G., The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nat. Med. 22:6 (2016), 624–631.
69. Singh, A.D., Parmar, S., Ramucirumab (Cyramza): a breakthrough treatment for gastric cancer. Pharm. Therapeut., 40(7), 2015, 430.
70. Li, J., Zhu, Z., Research and development of next generation of antibody-based therapeutics. Acta Pharmacol. Sin. 31:9 (2010), 1198–1207.
71. Tolentino, M., Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv. Ophthalmol. 56:2 (2011), 95–113.
72. Balaratnasingam, C., Dhrami-Gavazi, E., McCann, J.T., Ghadiali, Q., Freund, K.B., Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration. Clin. Ophthalmol. (Auckland, NZ), 9, 2015, 2355.
73. Stanel, S.C., Sjöberg, J., Salmonson, T., Foggi, P., Caleno, M., Melchiorri, D., Gravanis, I., Tzogani, K., Pignatti, F., European Medicines Agency approval summary: zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer. ESMO Open, 2(2), 2017, e000190.
74. Rupaimoole, R., Slack, F.J., MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 16:3 (2017), 203–222.
75. Zhou, Q., Anderson, C., Hanus, J., Zhao, F., Ma, J., Yoshimura, A., Wang, S., Strand and cell type-specific function of microRNA-126 in angiogenesis. Mol. Ther. 24:10 (2016), 1823–1835.
76. Laham-Karam, N., Lalli, M., Leinonen, N., Ylä-Herttuala, S., Differential regulation of vascular endothelial growth factors by promoter-targeted shRNAs. Mol. Ther.-Nucleic Acids, 4, 2015, e243.
77. van Beijnum, J.R., Giovannetti, E., Poel, D., Nowak-Sliwinska, P., Griffioen, A.W., miRNAs: micro-managers of anticancer combination therapies. Angiogenesis, 2017, 1–17.
78. Kim, S.H., Jeong, J.H., Lee, S.H., Kim, S.W., Park, T.G., PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Release 116:2 (2006), 123–129.
79. Alizadeh, N., Memar, M.Y., Moaddab, S.R., Kafil, H.S., Aptamer-assisted novel technologies for detecting bacterial pathogens. Biomed. Pharmacother. 93 (2017), 737–745.
80. Ng, E.W., Shima, D.T., Calias, P., Cunningham, E.T., Guyer, D.R., Adamis, A.P., Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5:2 (2006), 123–132.
81. Trujillo, C.A., Nery, A.A., Alves, J.M., Martins, A.H., Ulrich, H., Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology. Clin. Ophthalmol. 1:4 (2007), 393–402.
82. Sanz, L., Blanco, B., Alvarez-Vallina, L., Antibodies and gene therapy: teaching old ‘magic bullets’ new tricks. Trends Immunol. 25:2 (2004), 85–91.
83. Millauer, B., Shawver, L.K., Plate, K.H., Risaui, W., Ullrich, A., Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature, 367, 1994, 576.
84. Guijarro-Munoz, I., Compte, M., Alvarez-Vallina, L., Sanz, L., Antibody gene therapy: getting closer to clinical application?. Curr. Gene Ther. 13:4 (2013), 282–290.
85. Mahendra, G., Kumar, S., Isayeva, T., Mahasreshti, P.J., Curiel, D.T., Stockardt, C.R., Grizzle, W.E., Alapati, V., Singh, R., Siegal, G.P., Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Ther. 12:1 (2005), 26–34.
86. Al‐Husein, B., Abdalla, M., Trepte, M., DeRemer, D.L., Somanath, P.R., Antiangiogenic therapy for cancer: an update. Pharmacotherapy 32:12 (2012), 1095–1111.
87. Saharinen, P., Eklund, L., Pulkki, K., Bono, P., Alitalo, K., VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol. Med. 17:7 (2011), 347–362.
88. Kuczynski, E.A., Kerbel, R.S., Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma. Chin. J. Cancer, 35, 2016, 97.
89. Yang, H., Wang, Y., Cheryan, V.T., Wu, W., Cui, C.Q., Polin, L.A., Pass, H.I., Dou, Q.P., Rishi, A.K., Wali, A., Withaferin a inhibits the proteasome activity in mesothelioma in vitro and in vivo. PLoS One, 7(8), 2012, e41214.
90. Zhang, Y., Griffith, E.C., Sage, J., Jacks, T., Liu, J.O., Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc. Natl. Acad. Sci. 97:12 (2000), 6427–6432.
91. Grothey, A., Van Cutsem, E., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché O., Mineur, L., Barone, C., Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:9863 (2013), 303–312.
92. Folkman, U., Kalluri, R., Beginning of Angiogenesis Research, Holland-frei Cancer Medicine. 2003.
93. Murthy, R.C., McFarland, T.J., Yoken, J., Chen, S., Barone, C., Burke, D., Zhang, Y., Appukuttan, B., Stout, J.T., Corneal transduction to inhibit angiogenesis and graft failure. Invest. Ophthalmol. Vis. Sci. 44:5 (2003), 1837–1842.
94. Hanai, J.-i., Gloy, J., Karumanchi, S.A., Kale, S., Tang, J., Hu, G., Chan, B., Ramchandran, R., Jha, V., Sukhatme, V.P., Endostatin is a potential inhibitor of Wnt signaling. J. Cell Biol. 158:3 (2002), 529–539.
95. Wen, X.-Y., Bai, Y., Stewart, A.K., Adenovirus-mediated human endostatin gene delivery demonstrates strain-specific antitumor activity and acute dose-dependent toxicity in mice. Hum. Gene Ther. 12:4 (2001), 347–358.
96. Kuo, C.-H., Chang, B.-I., Lee, F.-T., Chen, P.-K., Lee, J.-S., Shi, G.-Y., Wu, H.-L., Development of recombinant adeno-associated virus serotype 2/8 carrying kringle domains of human plasminogen for sustained expression and cancer therapy. Hum. Gene Ther. 26:9 (2015), 603–613.
97. Feldman, A.L., Alexander, H.R., Hewitt, S.M., Lorang, D., Thiruvathukal, C.E., Turner, E.M., Libutti, S.K., Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J. Natl. Cancer Inst. 93:13 (2001), 1014–1020.
98. Blezinger, P., Wang, J., Gondo, M., Quezada, A., Mehrens, D., French, M., Singhal, A., Sullivan, S., Rolland, A., Ralston, R., Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat. Biotechnol. 17:4 (1999), 343–348.
99. Campochiaro, P.A., Lauer, A.K., Sohn, E.H., Mir, T.A., Naylor, S., Anderton, M.C., Kelleher, M., Harrop, R., Ellis, S., Mitrophanous, K.A., Lentiviral vector gene transfer of endostatin/angiostatin for macular degeneration (GEM) study. Hum. Gene Ther. 28:1 (2017), 99–111.
100. Smith, A.J., Oertle, J., Warren, D., Prato, D., Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: summary and perspective. J. Cell. Immunother. 2:2 (2016), 59–68.
101. Sha, H.-h., Wang, D.-d., Yan, D.-l., Hu, Y., Yang, S.-j., Liu, S.-w., Feng, J.-f., Chimaeric antigen receptor T-cell therapy for tumour immunotherapy. Biosci. Rep., 37(1), 2017, BSR20160332.
102. Holzer, T.R., Fulford, A.D., Nedderman, D.M., Umberger, T.S., Hozak, R.R., Joshi, A., Melemed, S.A., Benjamin, L.E., Plowman, G.D., Schade, A.E., Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung. PLoS One, 8(11), 2013, e80292.
103. Carmeliet, P., Jain, R.K., Angiogenesis in cancer and other diseases. Nature 407:6801 (2000), 249–257.
104. Chinnasamy, D., Yu, Z., Theoret, M.R., Zhao, Y., Shrimali, R.K., Morgan, R.A., Feldman, S.A., Restifo, N.P., Rosenberg, S.A., Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Invest. 120:11 (2010), 3953–3968.
105. Yong, C.S., Dardalhon, V., Devaud, C., Taylor, N., Darcy, P.K., Kershaw, M.H., CAR T-cell therapy of solid tumors. Immunol. Cell Biol., 2016.
106. Steeg, P.S., Targeting metastasis. Nat. Rev. Cancer 16:4 (2016), 201–218.
107. Kubota, Y., Tumor angiogenesis and anti-angiogenic therapy. Keio J. Med. 61:2 (2012), 47–56.
108. Vasudev, N.S., Reynolds, A.R., Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17:3 (2014), 471–494.
109. Ellis, L.M., Hicklin, D.J., VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8:8 (2008), 579–591.
110. Ranieri, G., Patruno, R., Ruggieri, E., Montemurro, S., Valerio, P., Ribatti, D., Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr. Med. Chem. 13:16 (2006), 1845–1857.
111. Herbst, R.S., O'Neill, V.J., Fehrenbacher, L., Belani, C.P., Bonomi, P.D., Hart, L., Melnyk, O., Ramies, D., Lin, M., Sandler, A., Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non–small-cell lung cancer. J. Clin. Oncol. 25:30 (2007), 4743–4750.
112. Wu, Y.-L., EGFR as a pharmacological target in EGFR-mutant non-small-cell lung cancer: where do we stand now?. Trends Pharmacol. Sci. 37:11 (2016), 887–903.
113. Ferrara, N., Adamis, A.P., Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 15:6 (2016), 385–404.
114. Clarke, J., Hurwitz, H., Rangwala, F., Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective. Cancer Treat. Rev. 40:9 (2014), 1065–1072.
115. Tabernero, J., Van Cutsem, E., Lakomý R., Prausová J., Ruff, P., van Hazel, G.A., Moiseyenko, V.M., Ferry, D.R., McKendrick, J.J., Soussan-Lazard, K., Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur. J. Cancer 50:2 (2014), 320–331.
116. Folprecht, G., Pericay, C., Saunders, M.P., Thomas, A., Lopez Lopez, R., Roh, J., Chistyakov, V., Höhler, T., Kim, J.-S., Hofheinz, R.-D., Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Ann. Oncol. 27:7 (2016), 1273–1279.
117. Verdaguer, H., Tabernero, J., Macarulla, T., Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther. Adv. Med. Oncol. 8:3 (2016), 230–242.
118. Arrieta, O., Zatarain-Barrón, Z.L., Cardona, A.F., Carmona, A., Lopez-Mejia, M., Ramucirumab in the treatment of non-small cell lung cancer. Expert Opin. Drug Saf. 16:5 (2017), 637–644.
119. Deng, H., Wang, Y., Ding, Q., Li, D., Wei, Y.-q., Gene therapy research in Asia. Gene Ther. 24:9 (2017), 572–577.
120. Ye, W., Liu, R., Pan, C., Jiang, W., Zhang, L., Guan, Z., Wu, J., Ying, X., Li, L., Li, S., Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma. Mol. Ther. 22:6 (2014), 1221–1229.
121. Xu, J., Tian, K., Zhang, H., Li, L., Liu, H., Liu, J., Zhang, Q., Zheng, J., Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens. Expert Rev. Anticancer Ther., 2017 (just-accepted).
122. Wang, W., Ma, Y., Li, J., Shi, H., Wang, L., Guo, F., Zhang, J., Li, D., Mo, B., Wen, F., Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. Gene Ther. 20:10 (2013), 970–978.
123. Parker, M., Bellec, J., McFarland, T., Scripps, V., Appukuttan, B., Hartzell, M., Yeager, A., Hady, T., Mitrophanous, K.A., Stout, T., Suppression of neovascularization of donor corneas by transduction with equine infectious anemia virus-based lentiviral vectors expressing endostatin and angiostatin. Hum. Gene Ther. 25:5 (2014), 408–418.
124. Almuhtaseb, H., Kanavati, S., Rufai, S., Lotery, A., One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration. Eye 31:6 (2017), 878–883.
125. Nirmal, J., Radhakrishnan, K., Moreno, M., Natarajan, J.V., Laude, A., Lim, T.H., Venkatraman, S., Agrawal, R., Drug, delivery and devices for diabetic retinopathy (3Ds in DR). Expert Opin. Drug Deliv. 13:11 (2016), 1625–1637.
126. Semeraro, F., Morescalchi, F., Duse, S., Parmeggiani, F., Gambicorti, E., Costagliola, C., Aflibercept in wet AMD: specific role and optimal use. Drug Des. Devel. Ther. 7 (2013), 711–722.
127. Lee, J., Kim, K.E., Choi, D.-K., Jang, J.Y., Jung, J.-J., Kiyonari, H., Shioi, G., Chang, W., Suda, T., Mochizuki, N., Angiopoietin-1 guides directional angiogenesis through integrin α v β 5 signaling for recovery of ischemic retinopathy. Sci. Transl. Med., 5(203), 2013 203ra127-203ra127.
128. Campochiaro, P.A., Khanani, A., Singer, M., Patel, S., Boyer, D., Dugel, P., Kherani, S., Withers, B., Gambino, L., Peters, K., Enhanced benefit in diabetic macular edema from AKB-9778 Tie2 activation combined with vascular endothelial growth factor suppression. Ophthalmology 123:8 (2016), 1722–1730.
129. Das, A., McGuire, P.G., Monickaraj, F., Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?. Indian J. Ophthalmol., 64(1), 2016, 4.
130. Davis, J.C., Furstenthal, L., Desai, A.A., Norris, T., Sutaria, S., Fleming, E., Ma, P., The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat. Rev. Drug Discov. 8:4 (2009), 279–286.
131. Jakka, S., Rossbach, M., An economic perspective on personalized medicine. Hugo J., 7(1), 2013, 1.
132. Henderson, D., Ogilvie, L.A., Hoyle, N., Keilholz, U., Lange, B., Lehrach, H., Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. Biotechnol. J. 9:9 (2014), 1104–1114.
133. Weston, A.D., Hood, L., Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J. Proteome Res. 3:2 (2004), 179–196.
134. Chen, R., Snyder, M., Systems biology: personalized medicine for the future?. Curr. Opin. Pharmacol. 12:5 (2012), 623–628.
135. Samant, R.S., Shevde, L.A., Recent advances in anti-angiogenic therapy of cancer. Oncotarget 2:3 (2011), 122–134.
136. Moserle, L., Jiménez-Valerio, G., Casanovas, O., Antiangiogenic therapies: going beyond their limits. Cancer Discov. 4:1 (2014), 31–41.
137. Lupo, G., Caporarello, N., Olivieri, M., Cristaldi, M., Motta, C., Bramanti, V., Avola, R., Salmeri, M., Nicoletti, F., Anfuso, C.D., Anti-angiogenic therapy in cancer: downsides and new pivots for precision medicine. Front. Pharmacol., 7, 2017, 519.